{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:05:15Z","timestamp":1792555515583,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Facial hyperhidrosis (HH), a common problem with both cosmetic and psychological impact, interferes with quality of life. Wide range of treatment options is available for HH. Finding the most effective and yet a safe, tolerable option is the main target.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate and compare clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial HH treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Twenty-four patients with primary facial HH were randomly divided into 2 equal groups: Group A included patients treated by intradermal Botulinum toxin A injection and Group B included patients treated by topical glycopyrrolate gel 2%. Starch iodine test was performed before and after treatment to assess response, along with Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index (DLQI), and patient satisfaction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Both modalities showed complete response in 75% of cases with a longer duration of action in botulinum toxin group up to 6 months. Side effects were minor and temporary. Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Topical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment with faster onset but shorter duration of action.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003490","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:02:37Z","timestamp":1655470957000},"page":"843-848","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature"],"prefix":"10.1097","volume":"48","author":[{"given":"Eman","family":"Nofal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaia","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrook A.","family":"Khashaba","sequence":"additional","affiliation":[{"name":"Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"e14658","DOI":"10.1111\/dth.14658","article-title":"Craniofacial hyperhidrosis: clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin","volume":"34","author":"Garcia-Souto","year":"2021","journal-title":"Dermatol Ther"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2010.03.013","article-title":"Clinical differentiation of primary from secondary hyperhidrosis","volume":"64","author":"Walling","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1503\/cmaj.1040708","article-title":"Focal hyperhidrosis: diagnosis and management","volume":"172","author":"Haider","year":"2005","journal-title":"CMAJ"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1524-4725.2009.01140.x","article-title":"Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk","volume":"35","author":"Kim","year":"2009","journal-title":"Dermatol Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2133.2000.03839.x","article-title":"Effective treatment of frontal hyperhidrosis with botulinum toxin A","volume":"143","author":"Kinkelin","year":"2000","journal-title":"Br J Dermatol"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2133.2008.08476.x","article-title":"Topical glycopyrrolate for patients with facial hyperhidrosis","volume":"158","author":"Kim","year":"2008","journal-title":"Br J Dermatol"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2003.12.029","article-title":"Multi-speciality working group on the recognition, diagnosis and treatment of primary focal hyperhidrosis","volume":"51","author":"Hornberger","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/bjd.12568","article-title":"Botulinum toxin for focal hyperhidrosis of the face","volume":"170","author":"George","year":"2014","journal-title":"Br J Dermatol"},{"key":"R9-20250731","first-page":"822","article-title":"Efficacy and safety of botulinum toxin type A in the treatment of palmer hyperhidrosis: a double blinded, randomized, placebo controlled study","volume":"28","author":"Lowe","year":"2002","journal-title":"Dermatol Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/1346-8138.15029","article-title":"Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B","volume":"46","author":"Cabreus","year":"2019","journal-title":"J Dermatol"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/jdv.12278","article-title":"Botulinum toxin B in the treatment of craniofacial hyperhidrosis","volume":"28","author":"Karlqvist","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11999-009-1119-9","article-title":"Patient satisfaction after total knee arthroplasty: who is satisfied and who is not?","volume":"468","author":"Bourne","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"R13-20250731","first-page":"729","article-title":"Hyperhidrosis: management options","volume":"97","author":"McConaghy","year":"2018","journal-title":"Am Fam Physician"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40257-015-0136-6","article-title":"Treatment of craniofacial hyperhidrosis: a systemic review","volume":"16","author":"Nicholas","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"De Paiva","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s004150070073","article-title":"Botulinum toxin for treatment of craniofacial hyperhidrosis","volume":"247","author":"Boger","year":"2000","journal-title":"J Neurol"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02444005","article-title":"Botulinum toxin in the therapy of gustatory sweating","volume":"243","author":"Schulze-Bonhage","year":"1996","journal-title":"J Neurol"},{"key":"R18-20250731","first-page":"644","article-title":"Therapy of Frey syndrome with botulinum toxin A. Experiences with a new method of treatment","volume":"43","author":"Drobik","year":"1995","journal-title":"HNO"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0378-6323.93647","article-title":"Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A","volume":"78","author":"Komericki","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jdv.12518","article-title":"Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double\u2010blinded, placebo\u2010controlled, split\u2010face study","volume":"29","author":"Hyun","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:07:18Z","timestamp":1753999638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003490","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}